1
Klaus Bornemann, Hans Briem, Cornelia Dorner Ciossek, Katja Fechteler, Klaus Fuchs, Frank Himmelsbach, Klaus Klinder, Markus Kostka: Trisubstituted pyrimidines. Boehringer Ingelheim Pharma & Co KG, Michael P Morris, Mary Ellen Devlin, Philip I Datlow, January 23, 2007: US07166599 (19 worldwide citation)

The present invention relates to trisubstituted pyrimidines of formula wherein Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses in which β-amyloid modulators have a therapeutic benefit, the use thereof for preparing a pharmaceutical composition with the abovement ...


2
Horst Dollinger, Gerd Schorrenberg, Hans Briem, Birgit Jung, Georg Speck: Neurokinin antagonists. Boehringer Ingelheim KG, Robert P Raymond, Wendy E Rieder, Alan R Stempel, December 9, 1997: US05696123 (18 worldwide citation)

The invention relates to new compounds of general formula I ##STR1## and the pharmaceutically acceptable salts thereof, wherein A, B, Z, R.sup.1, R.sup.2, R.sup.3 and m are defined as in the specification, processes for preparing them and pharmaceutical compositions containing these compounds. The c ...


3
Horst Dollinger, Gerd Schnorrenberg, Hans Briem, Birgit Jung, Georg Speck: Neurokinin antagonists. Boehringer Ingelheim KG, Robert P Raymond, Alan R Stempel, Mary Ellen Devlin, January 13, 1998: US05708006 (15 worldwide citation)

The invention relates to new compounds of general formula I ##STR1## and the pharmaceutically acceptable salts thereof, wherein A, B, Z, R.sup.1, R.sup.2, R.sup.3 and m are defined as in the specification, processes for preparing them and pharmaceutical compositions containing these compounds. The c ...


4
Horst Dollinger, Gerd Schnorrenberg, Hans Briem, Birgit Jung, Georg Speck: Neurokinin antagonists. Boehringer Ingelheim KG, Robert P Raymond, Anthony P Bottino, Alan R Stempel, November 16, 1999: US05985881 (15 worldwide citation)

The invention relates to new compounds of general formula I ##STR1## and the pharmaceutically acceptable salts thereof, wherein A, B, Z, R.sup.1, R.sup.2, R.sup.3 and m are defined as in the specification, processes for preparing them and pharmaceutical compositions containing these compounds. The c ...


5

6

7
Gerd Schnorrenberg, Horst Dollinger, Franz Esser, Hans Briem, Birgit Jung, Georg Speck: Arylglycinamide derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compounds. Boehringer Ingelheim KG, Robert P Raymond, Alan R Stempel, Mary Ellen Devlin, January 20, 1998: US05710155 (12 worldwide citation)

The invention relates to new arylglycinamide derivatives of general formula I ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and Ar have the meanings given in the specification, and the preparation and use thereof. The new compounds ar ...


8
Gerd Schnorrenberg, Horst Dollinger, Franz Esser, Hans Briem, Birgit Jung, Georg Speck: Arylglycinamide derivatives and pharmaceutical compositions containing these compounds. Boehringer Ingelheim KG, January 19, 1999: US05861509 (12 worldwide citation)

The invention relates to new arylglycinamide derivatives of general formula I ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and Ar have the meanings given in the specification, and the preparation and use thereof. The new compounds ar ...


9
Ulrich Luecking, Gerhard Siemeister, Martina Schaefer, Hans Briem: Macrocyclic pyrimidines, their production and use as pharmaceutical agents. Bayer Schering Pharma, Millen White Zelano & Branigan P C, December 25, 2007: US07312225 (6 worldwide citation)

Macrocyclic pyrimidine derivatives of general formula I in which R1 to R5, X, Y, A, B, m and n have the meanings that are contained in the description, as inhibitors of the cyclin-dependent kinase, their processes for production as well as their use as medications for treating various diseases are d ...


10